THE WHAT? Amorepacific Group reported first-quarter 2026 income and revenue progress, supported by sturdy derma skincare efficiency and worldwide enlargement.
THE DETAILS The corporate posted income of KRW 1.227 trillion (+5.0% YoY) and working revenue of KRW 137.8 billion (+6.9% YoY). Development was pushed by derma manufacturers together with AESTURA, COSRX, ILLIYOON and IOPE, alongside enlargement in North America by way of Amazon and robust efficiency in Japan from manufacturers resembling LANEIGE and HERA.
Its core subsidiary, Amorepacific, delivered income progress of 6.4% and working revenue progress of seven.6%. Domestically, income rose 9% and working revenue surged 65%, supported by sturdy luxurious gifting and channel efficiency. Abroad income elevated 6%, with double-digit progress in Western markets and APAC, although working revenue declined 18% on account of elevated advertising and marketing funding and continued restructuring in China.
Key highlights included triple-digit progress for AESTURA in North America, COSRX returning to progress globally, and LANEIGE strengthening its place throughout Japan and APAC. In the meantime, some smaller subsidiaries noticed declines on account of offline channel restructuring.
THE WHY? The outcomes mirror Amorepacific’s strategic pivot in the direction of high-growth derma skincare, world channel diversification and digital enlargement, whereas continued funding in worldwide markets and restructuring efforts impression short-term profitability.
Supply: Amorepacific Group
